Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer
NCT06367335
·
clinicaltrials.gov ↗
COMPLETED
Status
128
Enrollment
OTHER
Sponsor class
Conditions
DILI
Interventions
DRUG:
Ribociclib, palbociclib, abemaciclib
Sponsor
University of Milano Bicocca